According to the Centers of Disease Control and Prevention (CDC), approximately 2.8 million people in the U.S. are infected by antibiotic-resistant bacteria each year. It is estimated that antibioticresistant Staphylococcus aureus accounted for over 300,000 hospitalizations and over 10,000 deaths in 2017, indicating that S. aureus is a key contributor to the burden of antibiotic-resistant infections (CDC). S. aureus is a Gram-positive bacterium that asymptomatically colonizes 20%-30% of the population, predominately in the anterior nares and the skin (Lowy, 1998). Despite being asymptomatic, S. aureus can opportunistically establish infections in nearly every anatomical site but most commonly causes infections in the skin (Pallin et al., 2008;Suaya et al., 2014). This bacterium is responsible for most of the skin and soft-tissue infections observed in the clinic (Moran et al., 2006) and was estimated to cost the U.S. healthcare system $1.7 billion in 2017 (CDC). With the large burden that S. aureus places on the healthcare system, an emphasis on understanding what makes S. aureus such a successful pathogen and designing novel targeted therapeutics is needed.
S. aureus must be able to adapt to individual niches on and withinthe host to ensure well-timed regulation of its virulence arsenal to be a successful pathogen. Environmental cues include changes in osmolarity, temperature, presence, or absence of oxygen, pH, and host-associated factors. Some of these signals are sensed by two-component systems (TCS) which allow bacteria to respond to stimuli and adjust target gene expression accordingly (Tiwari et al., 2017;Wang, 2012). S. aureus possesses 16 TCS that respond to